{
  "id": 13509692,
  "title": "Pacira BioSciences SVP Lauren Riker sells $217,920 in stock",
  "url": "https://urgent.news/2026/10/10/pacira-biosciences-svp-lauren-riker-sells-217-920-in-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-10T19:31:05.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/pacira-biosciences-svp-lauren-riker-sells-217920-in-stock-93CH-4942219"
  },
  "original_language": "en",
  "account": "Lauren Riker, Senior Vice President of Finance at Pacira BioSciences, sold 6,000 shares of the company's common stock for a total of $217,920 on October 8, 2026. She exercised options to acquire 6,000 shares at $32.35 per share, totaling $194,100. These shares were then sold at $36.32 each. The sale occurred as the stock traded near its 52-week high of $36.46, following a 44% gain over a week and a 62% return over the past year. Both actions followed a Rule 10b5-1 trading plan, adopted by Ms. Riker on March 12, 2026. The stock option vested over time, with 25% becoming exercisable after a year and the rest in quarterly installments over three years. Following the transactions, Ms. Riker holds 62,284.242 shares of Pacira BioSciences common stock. The stock is currently considered undervalued, with a Piotroski Score of 9, indicating strong financial health. Pacira BioSciences reported a 6% revenue increase in Q2, reaching $192.4 million, surpassing expectations. Viatris acquired Pacira Pharmaceuticals for $1.65 billion, leading to a downgrade of the stock rating to 'Hold' by Jefferies. Oppenheimer initiated coverage with an 'outperform' rating and a price target of $32.00.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Pacific Biosciences CFO reports $2.05m stock sale",
        "url": "https://urgent.news/2026/10/10/pacific-biosciences-cfo-reports-2-05m-stock-sale",
        "published": "2026-10-10T17:31:05.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}